Literature DB >> 16680018

The inhibition of inducible nitric oxide synthase in ovine sepsis model.

Perenlei Enkhbaatar1, Kazunori Murakami, Lillian D Traber, Robert Cox, John F Parkinson, Martin Westphal, Aimalohi Esechie, Naoki Morita, Marc O Maybauer, Dirk M Maybauer, Ann S Burke, Frank C Schmalstieg, Hal K Hawkins, David N Herndon, Daniel L Traber.   

Abstract

Excessive NO has been shown to play a major role in the pathogenesis of multiple organ dysfunctions in septic condition. Burn injury, especially if it is associated with smoke inhalation, is often complicated by subsequent development of pneumonia or sepsis that determine the outcome. In the present study, we developed an ovine sepsis model, created by exposing sheep to smoke inhalation followed by instillation of bacteria into the airway, that closely mimics human sepsis and pneumonia. We hypothesized that the inhibition of iNOS-derived excessive NO might be beneficial in treating the cardiopulmonary derangement in this model. Female sheep (n = 18) were surgically prepared for the study and given a tracheostomy. This was followed by insufflation of 48 breaths of cotton smoke (< 40 degrees C) into the airway of each animal and subsequent instillation of live Pseudomonas aeruginosa (5 x 10(11) colony forming units) into each sheep's lung. All sheep were mechanically ventilated using 100% O2. Continuous infusion of BBS-2 (100 microg/kg/h), an iNOS inhibitor, was started 1 h after insult. The administration of BBS-2 improved pulmonary gas exchange (PaO2/FiO2 and pulmonary shunt fraction) and partially reduced airway obstruction and an increase in ventilatory pressures. The lung water content was not affected by iNOS inhibition. The hypotension seen in nontreated animals was not ameliorated either. The increase in plasma concentration of nitrate and nitrite was inhibited by BBS-2. The results of present study show that iNOS may be partially involved in the pathogenesis of acute lung injury induced by smoke inhalation followed by bacterial instillation in the airway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16680018     DOI: 10.1097/01.shk.0000209525.50990.28

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  16 in total

1.  Pseudomonas aeruginosa is associated with increased lung cytokines and asymmetric dimethylarginine compared with methicillin-resistant Staphylococcus aureus.

Authors:  Linda E Sousse; Collette C Jonkam; Daniel L Traber; Hal K Hawkins; Sebastian W Rehberg; Lillian D Traber; David N Herndon; Perenlei Enkhbaatar
Journal:  Shock       Date:  2011-11       Impact factor: 3.454

2.  The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.

Authors:  Marc O Maybauer; Dirk M Maybauer; Perenlei Enkhbaatar; Régent Laporte; Halina Wiśniewska; Lillian D Traber; ChiiDean Lin; Juanjuan Fan; Hal K Hawkins; Robert A Cox; Kazimierz Wiśniewski; Claudio D Schteingart; Donald W Landry; Pierre J-M Rivière; Daniel L Traber
Journal:  Crit Care Med       Date:  2014-07       Impact factor: 7.598

3.  Beneficial effects of concomitant neuronal and inducible nitric oxide synthase inhibition in ovine burn and inhalation injury.

Authors:  Matthias Lange; Atsumori Hamahata; Perenlei Enkhbaatar; Robert A Cox; Yoshimitsu Nakano; Martin Westphal; Lillian D Traber; David N Herndon; Daniel L Traber
Journal:  Shock       Date:  2011-06       Impact factor: 3.454

4.  Molecular biological effects of selective neuronal nitric oxide synthase inhibition in ovine lung injury.

Authors:  Fiona D Saunders; Martin Westphal; Perenlei Enkhbaatar; Jianpu Wang; Konrad Pazdrak; Yoshimitsu Nakano; Atsumori Hamahata; Collette C Jonkam; Matthias Lange; Rhykka L Connelly; Gabriela A Kulp; Robert A Cox; Hal K Hawkins; Frank C Schmalstieg; Eszter Horvath; Csaba Szabo; Lillian D Traber; Elbert Whorton; David N Herndon; Daniel L Traber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-04       Impact factor: 5.464

5.  Combined neuronal and inducible nitric oxide synthase inhibition in ovine acute lung injury.

Authors:  Matthias Lange; Rhykka Connelly; Daniel L Traber; Atsumori Hamahata; Robert A Cox; Yoshimitsu Nakano; Kamna Bansal; Aimalohi Esechie; Sanna von Borzyskowski; Collette Jonkam; Lillian D Traber; Hal K Hawkins; David N Herndon; Perenlei Enkhbaatar
Journal:  Crit Care Med       Date:  2009-01       Impact factor: 7.598

6.  Right man, right time, right place?--on the time course of the mediator orchestra in septic shock.

Authors:  Balázs Hauser; Peter Radermacher
Journal:  Crit Care       Date:  2010-08-23       Impact factor: 9.097

7.  Hypoxia attenuates effector-target cell interaction in the airway and pulmonary vascular compartment.

Authors:  S Meyer; B R Z'graggen; S Blumenthal; A Borgeat; M T Ganter; L Reyes; C Booy; T A Neff; D R Spahn; B Beck-Schimmer
Journal:  Clin Exp Immunol       Date:  2007-09-24       Impact factor: 4.330

8.  Beneficial effect of a hydrogen sulphide donor (sodium sulphide) in an ovine model of burn- and smoke-induced acute lung injury.

Authors:  Aimalohi Esechie; Perenlei Enkhbaatar; Daniel L Traber; Collette Jonkam; Matthias Lange; Atsumori Hamahata; Clarisse Djukom; Elbert B Whorton; Hal K Hawkins; Lillian D Traber; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

9.  TNF is a key mediator of septic encephalopathy acting through its receptor, TNF receptor-1.

Authors:  Jessy J Alexander; Alexander Jacob; Patrick Cunningham; Lauren Hensley; Richard J Quigg
Journal:  Neurochem Int       Date:  2007-08-17       Impact factor: 3.921

10.  Pulmonary vascular permeability changes in an ovine model of methicillin-resistant Staphylococcus aureus sepsis.

Authors:  Collette C Jonkam; Kamna Bansal; Daniel L Traber; Atsumori Hamahata; Marc O Maybauer; Dirk M Maybauer; Robert A Cox; Matthias Lange; Rhykka L Connelly; Lillian D Traber; Clarisse D Djukom; John R Salsbury; David N Herndon; Perenlei Enkhbaatar
Journal:  Crit Care       Date:  2009-02-17       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.